Ferric carboxymaltose with or without erythropoietin for the prevention of red-cell transfusions in the perioperative period of osteoporotic hip fractures: A randomized contolled trial. the PAHFRAC-01 project

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Bernabeu Wittel, Máximo ^a   Aparicio, Reyes ^b   Romero, Manuel ^c   Murcia Zaragoza, José ^d   Monte Secades, Rafael ^e   Rosso, Clara ^a   Montero, Abelardo ^f   Ruiz Cantero, Alberto ^g   Melero Bascones, María ^h  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL SAN JUAN DE DIOS DEL ALJARAFE   (Spain)

^c HOSPITAL INFANTA ELENA   (Spain)

^d HOSPITAL VEGA BAJA   (Spain)

^e HOSPITAL XERAL CALDE   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g Hospital de la Serrania   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Blood saving strategies; Clinical trial; Erythropoietin; Ferric carboxymaltose; Hip fracture; Red cell pack; Transfusion

Indexed keywords

ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; PLACEBO; DRUG DERIVATIVE; FERRIC ION; MALTOSE;

ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; HIP FRACTURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; PARALLEL DESIGN; PERIOPERATIVE PERIOD; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SURGICAL MORTALITY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; AGED; ANEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; FEMALE; FRAGILITY FRACTURE; MALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE HEMORRHAGE; UTILIZATION REVIEW;

AGED; AGED, 80 AND OVER; ANEMIA; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; FERRIC COMPOUNDS; HIP FRACTURES; HUMANS; MALE; MALTOSE; OSTEOPOROTIC FRACTURES; POSTOPERATIVE HEMORRHAGE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84857125051     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-27     Document Type: Article

References (34)

1. Epidemiology of hip fracture in the elderly in Spain. Alvarez-Nebreda ML, Jiménez AB, Rodríguez P, Serra JA, Bone 2008 42 278 285 10.1016/j.bone.2007.10.001 18037366
2. The future of hip fractures in the United States: numbers, costs, and potential effects of postmenopausal estrogen. Cummings SR, Rubin SM, Black D, Clin Orthop 1990 252 163 166 2302881 (Pubitemid 20109433)
3. Epidemiology of hip fractures. Kannus P, Parkkari J, Sievännen H, Heinonen A, Vuori I, Järvinen M, Bone 1996 18 suppl 1 57S 63S 8717549 (Pubitemid 26047545)
4. Prognostic indicators and early home rehabilitation in elderly patients with hip fractures. Ceder L, Thorngren KG, Wallden B, Clin Orthop 1980 152 173 184 7438601 (Pubitemid 11199827)
5. Functional recovery after hip fracture. Jette AM, Harris BA, Cleary PD, et al. Arch Phys Med Rehabil 1987 68 735 740 3662784 (Pubitemid 17149892)
6. Las fracturas de cadera suponen un coste de 25000 millones de euros al ão en la UE. ReES 2005 4 216 217
7. A pilot randomized trial comparing symptomatic vs. hemoglobin-level- driven red blood cell transfusions following hip fracture. Carlson JL, Terrin ML, Barton FB, et al. Transfusion 1998 38 522 529 10.1046/j.1537-2995.1998. 38698326331.x 9661685 (Pubitemid 28317227)
8. Iron metabolism and erythropoiesis after surgery. Van Iperen CE, Kraaijenhagen RJ, Biesma DH, et al. Br J Surg 1998 85 41 45 10.1046/j.1365-2168. 1998.00571.x 9462381 (Pubitemid 28034109)
9. Transfusion medicine. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP, N Engl J Med 1999 340 438 447 10.1056/NEJM199902113400606 9971869 (Pubitemid 29084776)
10. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP, J Trauma 2003 54 908 914 10.1097/01.TA.0000022460.21283. 53 12777903 (Pubitemid 36758801)
11. Perioperative blood transfusion and postoperative mortality. Carson JL, Duff A, Berlin JA, et al. JAMA 1998 279 199 205 10.1001/jama.279.3.199 9438739 (Pubitemid 28133781)
12. Análisis del impacto presupuestario de la implantacián de medidas de ahorro de sangre en cirugía de urgencia. Izuel Rami M, Gámez Barrera M, Villar Fernández I, et al. Medicina Clínica (Barc.) 2007 128 1 7 11 22359625 (Pubitemid 46232726)
13. Interdisciplinary inpatient care for elderly people with hip fracture: a randomized controlled trial. Naglie G, Tansey C, Kirkland JL, et al. CMAJ 2002 167 25 32 12137074 (Pubitemid 34734929)
14. Efectividad de las distintas pautas de tratamiento de la anaemia perioperatoria en pacientes ancianos con fractura de cadera. Izuel-Rami M, Cuenca Espiérrez J, García-Erce JA, et al. Farm Hosp 2005 29 250 257 10.1016/S1130-6343(05)73673-4 16268741 (Pubitemid 41617533)
15. Intravenous iron and recombinant erythropoietin for the treatment of postoperative anaemia. Karnouki K, McCluskey SA, Grahnnam M, et al. Can J Anesth 2006 53 11 19 10.1007/BF03021522 16371604 (Pubitemid 43230987)
16. Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: a pilot study. Cuenca J, García-Erce JA, Mũoz M, et al. Transfusion 2004 44 1447 1452 10.1111/j.1537-2995.2004. 04088.x 15383017 (Pubitemid 39318979)
17. A novel intravenous iron formulation for treatment of anaemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. Am J Gastroenterol 2008 103 1182 1192 10.1111/j.1572-0241. 2007.01744.x 18371137 (Pubitemid 351677967)
18. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anaemia. Breymann C, Gliga F, Bejenariu C, Strizhova N, Int J Gynaecol Obstet 2008 101 67 73 10.1016/j.ijgo.2007.10.009 18234203
19. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anaemia: a randomized controlled trial. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A, Obstet Gynecol 2007 110 267 278 10.1097/01.AOG.0000275286.03283.18 17666600 (Pubitemid 47356650)
20. La versián espãola del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos. Alonso J, Prieto L, Anto JM, Med Clin (Barc) 1995 104 771 776
21. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. Cuenca J, García-Erce A, Martínez AA, et al. Arch Orthop Trauma Surg 2005 125 342 347 10.1007/s00402-005-0809-3 15789233 (Pubitemid 40895356)
22. Perioperative blood management practices in elective orthopaedic surgery. Keating EM, Meding JB, J Am Acad Orthop Surg 2002 10 393 400 12470041
23. Perioperative epoetin alfa increases red blood cell mass and reduces exposure to transfusions: results of randomized clinical trials. Goldberg MA, Semin Hematol 1997 34 41 47 9253783 (Pubitemid 27319144)
24. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group. Faris PM, Ritter MA, Abels RI, J Bone Joint Surg Am 1996 78 62 72 8550681 (Pubitemid 26028674)
25. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Goldberg MA, McCutchen JW, Jove M, Di Cesare P, Friedman RJ, Poss R, Guilfoyle M, Frei D, Young D, Am J Orthop 1996 25 544 552 8871752
26. Preoperative administration of epoetin alfa to reduce transfusion requirements in elderly patients having primary total hip or knee reconstruction. Lofthouse RA, Boitano MA, Davis JR, Jinnah RH, J South Orthop Assoc 2000 9 175 181 12135299 (Pubitemid 33262643)
27. Preoperative administration of epoetin alfa to total joint arthroplasty patients. Rauh MA, Bayers-Thering M, LaButti RS, Krackow KA, Orthopedics 2002 25 317 320 11918037 (Pubitemid 34284800)
28. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. de Andrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC, Am J Orthop 1996 25 533 542 8871751
29. Intravenous iron: from anathema to standard of care. Auerbach M, Coyne D, Ballard H, Am J Hematol 2008 83 580 588 10.1002/ajh.21154 18273906 (Pubitemid 351874877)
30. Intravenous administration of iron in epoetin-treated haemodialysis atients - which drugs, which regimen? MacDougall IC, Nephrol Dial Transplant 2000 15 1743 1745 10.1093/ndt/15.11.1743 11071957
31. Bloodless medicine: clinical care without allogeneic blood transfusion. Goodnough LT, Shander A, Spence R, Transfusion 2003 43 668 676 10.1046/j.1537-2995.2003.00367.x 12702192 (Pubitemid 36506366)
32. Parenteral iron therapy options. Silverstein SB, Rodgers GM, Am J Hematol 2004 76 74 78 10.1002/ajh.20056 15114602 (Pubitemid 38579543)
33. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, N Engl J Med 2009 361 2436 2448 10.1056/NEJMoa0908355 19920054
34. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Bisbe E, García-Erce JA, Díez-Lobo AI, Mũoz M, Br J Anaesth 2011 107 477 478 10.1093/bja/aer242 21841061